



ISSUER RATING
Long term

OUTLOOK
Stable



INSTRUMENT RATING
Neu MTN



ISSUER RATING
Short-term



INSTRUMENT RATING
Neu CP

Initiation date 29/11/2022
Rating Date 28/06/2024

Contacts

Lead analyst

Anne Guy
anne.guy@ethifinance.com

Committee chair

Marc Pierron
marc.pierron@ethifinance.com

Rating action and rationale

- EthiFinance Ratings affirms both its long-term rating for Sofiproteol SA and for the NEU MTN programme for up to €75m, at A-, maintaining a Stable outlook. EthiFinance Ratings also affirms its short-term rating of EF1 for Sofiproteol SA, and a rating of EF1 for its NEU CP programme for up to €300m.
- The reaffirmation of our ratings is primarily due to an excellent financial profile over the past two years, one which is expected to be maintained over our forecast period, until 2026. It is characterized by a slightly negative loan-to-value ratio, on the back of a prudent financial policy. In addition, Sofiproteol has a rather cautious investment policy, as demonstrated by a well-diversified portfolio by value that excludes the use of significant leverage. Sofiproteol's track record of gains on divestments over the past few years also supports our ratings. Regarding Sofiproteol's bond portfolio, it is well diversified with a good liquidity profile.
- However, our ratings are constrained by the rather low level of diversification in terms of industries and geography as Sofiproteol's equity investments are mainly concentrated in the agribusiness in France. Moreover, equity investments are relatively illiquid since most companies in which the company invests are not listed. Finally, the credit quality of those companies is on average lower than that of Sofiproteol, which weighs on the ratings.
- In terms of ESG issues, Sofiproteol is committed to sustainable agriculture and food production. This is particularly visible for the equity investments division, for which Sofiproteol incorporates ESG KPIs regarding safety, management, and GHG emissions, into its investment policy. The portfolio of bonds is more diversified in terms of industries covered, and by extension less oriented towards positive ESG sectors.

Issuer description

Sofiproteol SA is an investment company, a subsidiary of the French group Avril, which is specialised in the industrial processing and transformation of oilseed grains into oils and proteins. Avril SCA, the ultimate holding company of Avril, currently owns 70.9% of the investment company, the rest being owned by financial institutions and companies from the agricultural world. Sofiproteol is regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR), the body in charge of monitoring banking and insurance activities in France.

Sofiproteol was created in 1983, originally as an investment vehicle granting term loans and taking minority stakes in companies in the oils and protein industries in France, before it became an industrial group itself, changing its name to Avril. In 2015, Sofiproteol became an independent investment company with two separate businesses within the Avril group. First, it invests in agribusinesses and food sectors, especially companies in the oils and protein sub-sectors, using Sofiproteol's equity. Investments are mainly made through minority equity stakes with a medium-to-long-term time horizon. Depending on the needs of the companies, Sofiproteol may also invest through bonds and set up current accounts in addition to its equity investments. This business accounts for around 50% of total adjusted assets including cash and cash equivalents. Sofiproteol's investment strategy aims at fostering the development of the agricultural sector. Second, in order to optimize cash not invested in equity, bonds or current accounts, Sofiproteol manages a portfolio of assets which mainly comprises bonds and term deposits (TDs), using some leverage effect. This accounts for the remaining 50% of the company's assets.

Due to the nature of Sofiproteol's activities, our analysis is based on our 'investment holding methodology'.

Fundamentals

Business profile

Investment policy

- **Prudent investment policy with a good track record and ESG considerations**

Our ratings remain underpinned by Sofiproteol's very good credit metrics, which result from its prudent investment policy and good track record. These metrics have been reinforced by some significant gains made over the past few years despite the consequences of the pandemic.

In addition, since 2022, Sofiproteol has reviewed its investment policy to align it with the various pillars of Avril's stated purpose, "Serving the Earth". In particular, Sofiproteol has integrated the commitment of "acting for the impact of our investments", which aims at anchoring sustainable agriculture and food production in the areas of operation. As a consequence, it has integrated ESG criteria into its investment policy for equity and sustainability linked debts, in particular safety KPIs, management best practices, and GHG emissions targets (scope 1 and 2). Regarding its portfolio of bonds, the part of green bonds or sustainability-linked loans is now evaluated. However, the portfolio being more diversified in terms of industry covered, it is less oriented towards positive ESG sectors.

Portfolio of investments

- **Good diversification in value with moderate sector and geographic diversification**

Sofiproteol's portfolio has very good diversification by value as the main equity investment accounted for c. 14% of total adjusted investments in equity at end-2023. However, our ratings are constrained by equity investments being mainly focused on France, and in the agribusiness sector. Regarding the bond portfolio, it is well diversified with a significant number of lines, and a wide exposure to industries and geographies.

- **Excellent credit quality of debt investments, constrained by equity investments**

The vast majority of bonds held by Sofiproteol at end-2023 were investment grade. The average credit quality of the assets is, however, partly lowered by equity investments, which comprise companies with credit quality below investment grade on average, albeit some companies among the top 5 in value continue to report solid credit metrics.

- **Liquidity of assets constrained by rather illiquid equity investments despite good liquidity for bonds and term deposits**

Our ratings are also partly constrained by the illiquidity of the equity investments, given the unlisted nature of most of the companies concerned as well as Sofiproteol's strategy of long-term investment. However, the low level of financial debt and the good liquidity of bonds and TDs enable Sofiproteol to maintain a good corporate liquidity profile, which contributes positively to our ratings.

Financial profile

Financial policy

- **Prudent financial policy**

We assess Sofiproteol's financial policy as prudent given its low level of financial debt and excellent loan-to-value (LTV) ratio.

Leverage and coverage

- **Excellent credit metrics with a net cash position**

The EthiFinance Ratings-adjusted LTV ratio was negative at end-2023 and is expected to remain negative over our forecast horizon (three years). The interest coverage ratio - FFO / (interest + mandatory dividend payable) - deteriorated in FY23 compared with the previous year, on the back of higher cash interest expenses. Over the forecast period (2024-26), despite interest rates which should remain high, we expect the ratio to improve on the back of a good cash generation.

At end-2023, Sofiproteol's gross debt principally comprised €164m of REPOs, and €82m of NEU CP. The remainder consisted of various credit lines and cash pooling totalling €37m. According to our rating methodology, and our interpretation of Sofiproteol's business, cash and cash equivalents amounted to €175m at end-2023 and mainly consisted of TDs. We have also factored in €164m of bonds to match the amount of repo debt, resulting in a net cash position of €56m as at end-2023.

Liquidity profile

- **'Superior' liquidity profile with solid cash position**

Sofiproteol's liquidity profile is assessed as 'Superior' thanks to a solid cash position as at end-2023. Based on our methodology and our projections, the liquidity level should remain strong, helped by the last tranche of the share capital increase planned for 2024 as well as some divestments and despite some significant investments. Depending on liquidity needs, Sofiproteol may also adapt its investment strategy, which reinforces its good liquidity profile.

Credit metrics expected evolution (CMEE)

- **Stable outlook despite significant investments expected**

Our Stable CMEE reflects our view that despite significant investments expected in the forthcoming year, credit metrics are expected to remain broadly unchanged.

Rating sensitivity

- **Rating list:**
 - LT issuer rating: A-
 - NEU MTN rating: A-
 - ST issuer rating: EF1
 - NEU CP rating: EF1

Factors that may (individually or collectively) impact the rating:

- **Positive factors (↑)**

One major driver for an upgrade of our LT ratings would be a sustainable improvement in the interest coverage ratio (towards 3.5x). An upgrade could also derive from better overall diversification, especially with respect to industry investments and geography, and/or an improvement in the overall quality/liquidity of the company's assets, especially its equity investments.

An upgrade of our short-term ratings would derive from an upgrade of our long-term corporate rating.

- **Negative factors (↓)**

We may downgrade our long-term ratings in the event of a deterioration of credit metrics, especially the interest coverage and LTV ratios, and/or the adoption of a more aggressive financial policy. A downgrade of our short-term ratings is improbable at present and would require significant unforeseen change in credit metrics or liquidity.

Sources of information

The credit rating assigned in this report has been requested by the rated entity, which has also taken part in the process. It is based on private information as well as public information. The main sources of information are:

1. Annual Audit Reports.
2. Corporate Website.
3. Information published in the Official Bulletins.
4. Rating book provided by the Company.

The information was thoroughly reviewed to ensure that it is valid and consistent, and is considered satisfactory. Nevertheless, EthiFinance Ratings assumes no responsibility for the accuracy of the information and the conclusions drawn from it.

Conditions of Use for this document and its content:

For all types of Ratings that ETHIFINANCE RATINGS, S.L. (the "AGENCY") issues, the User may not, either by themselves or via third parties, transfer, sublease, sublicense, sell, extract, reuse, or dispose of in any other way the content of this Document to a third party, either for free or for consideration.

For the purpose of these Conditions of Use, any client who might have subscribed for a product and/or a service that allows him to be provided with the content of this Document as well as any privileged person who might access the content of this Document via www.ethifinance.com shall be considered as a User.

Nor may they alter, transform or distort the information provided in any way. In addition, the User will also not be permitted to copy and/or duplicate the information, nor create files which contain the information of the Document, either in its entirety or partially. The Document and its source code, regardless of the type, will be considered as the elaboration, creation, or work of the AGENCY and subject to the protection of intellectual property right regulation. For those uses of this Document which are permitted, the User is obliged to not allow the removal of the copyright of the AGENCY, the date of the Document's issuance, the business name as established by the AGENCY, as well as the logo, brands and any other distinctive symbol which is representative of the AGENCY and its rights over the Document. The User agrees to the conditions of Use of this Document and is subject to these provisions since the first time they are provided with this Document no matter how they are provided with the document. The Document and its content may not be used for any illicit purpose or any purpose other than those authorised by the AGENCY. The User will inform the AGENCY about any unauthorised use of the Document and/or its content that may become apparent. The User will be answerable to the AGENCY for itself and its employees and/or any other third party which has been given or has had access to the Document and/or its content in the case of damages which arise from the breach of obligations which the User declared to have read, accepted and understood upon receiving the Document, without prejudice to any other legal actions that the AGENCY may exercise in defence of its lawful rights and interests. The Document is provided on the acceptance that the AGENCY is not responsible for the interpretation that the User may make of the information contained. Credit analyses included in the Document, as well as the ratings and statements, are to be deemed as opinions valid on the date of issuance of the reports and not as statements of fact or recommendations to purchase, hold or sell any securities or to make any investment decision. The credit ratings and credit rating prospects issued by the AGENCY are consider to be its own opinion, so it is recommended that the User take it as a limited basis for any purpose that it intends to use the information for. The analyses do not address the suitability of any value. The AGENCY does not act as a fiduciary or an investment advisor, so the content of the Document should not be used as a substitute for knowledge, criteria, judgement or experience of the User, its Management, employees, advisors and/or clients in order to make investment decisions. The AGENCY will devote every effort to ensure that the information delivered is both accurate and reliable. Nonetheless, as the information is elaborated based on data supplied by sources which may be beyond the control of the AGENCY, and whose verification and comparison is not always possible, the AGENCY, its subsidiaries, and its directors, shareholders, employees, analysts and agents will not bare any responsibility whatsoever (including, without any limitations, loss of revenue or income and opportunity costs, loss of business or reputational damage or any other costs) for any inaccuracies, mistakes, noncorresponding information, incompleteness or omission of data and information used in the elaboration of the Document or in relation to any use of its content even should it have been warned of potential damages. The AGENCY does not make audits nor assume the obligation of verifying independent sources of information upon which the ratings are elaborated. Information on natural persons that may appear in this document is solely and exclusively relevant to their business or business activities without reference to the sphere of their private life and should thus be considered. We would like to inform that the personal data that may appear in this document is treated in accordance with Regulation (EU) 679/2016, on the protection of natural persons with regard to the processing of personal data and the free movement of such data and other applicable legislation. Those interested parties who wish to exercise the rights that assist them can find more information in the link: <https://www.ethifinance.com/> in the Privacy Policy page or contact our Data Protection Officer in the mail dpo@ethifinance.com. Therefore the User agrees that information provided by the AGENCY may be another element to consider when making business decisions, but decisions will not be made based solely on it; that being the case the AGENCY will not be held responsible for the lack of suitability. In addition, the use of the information before courts and/or tribunals, public administrations, or any other public body or private third party for any reason shall be solely the User's responsibility and the AGENCY shall not be held responsible for any liabilities on the grounds of inappropriateness of the information's contents. Copyright © 2023 ETHIFINANCE RATINGS, S.L. All Rights Reserved. C/ Benjamín Franklin S/N, Edificio Camt, 1º Izquierda, 18100, Granada, España C/ Velázquez nº18, 3º derecha, 28001 - Madrid